Matin Surena F, Ahrar Kamran, Wood Christopher G, Daniels Molly, Jonasch Eric
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
BJU Int. 2008 Sep;102(8):940-5. doi: 10.1111/j.1464-410X.2008.07718.x. Epub 2008 May 15.
To review the records of patients at our centre with von Hippel-Lindau (VHL) disease, to determine the incidence of renal cell carcinoma (RCC) and patterns of intervention using minimally invasive therapies.
Patients with genetically confirmed VHL were evaluated in a multidisciplinary clinical care centre established in 2003. Patients were preferentially offered percutaneous radiofrequency ablation (RFA). Cystic tumours were considered contraindications to RFA, as were larger tumours or extensive multifocality with tumours of >3 cm. These patients had either open partial nephrectomy (OPN) or, in unsalvageable cases, radical nephrectomy.
Of 38 patients with VHL, 16 (42%) were found to have RCC; two with small tumours are under observation. Fourteen of the 16 have had a total of 25 renal interventions, none of whom has progressed to end-stage renal disease. OPN was performed in 15 (60%) cases, including those who had had multiple bilateral procedures; RFA was used in five (20%) cases. After median follow-up of 41 months, local recurrence was detected in 33%; the metastasis-free survival rate was 93.3% and overall survival 87.5%.
Of patients with VHL, 88% with renal involvement require interventions for their kidneys. OPN is the primary method used, and was successful both as a primary and secondary procedure in 60% of cases. In only 20% was RFA possible due to limitations of current technology. The introduction of protocol-based targeted therapies holds the promise of reducing the number of interventions required for treating VHL.
回顾我院中心患有冯·希佩尔-林道(VHL)病患者的病历,以确定肾细胞癌(RCC)的发病率以及使用微创治疗的干预模式。
在2003年建立的多学科临床护理中心对基因确诊为VHL的患者进行评估。优先为患者提供经皮射频消融(RFA)治疗。囊性肿瘤被视为RFA的禁忌证,较大肿瘤或肿瘤直径>3 cm的广泛多灶性肿瘤也同样如此。这些患者接受了开放性部分肾切除术(OPN),在无法挽救的情况下则接受根治性肾切除术。
38例VHL患者中,16例(42%)被发现患有RCC;2例小肿瘤患者正在观察中。16例中的14例共进行了25次肾脏干预,均未进展至终末期肾病。15例(60%)进行了OPN,包括那些接受过多次双侧手术的患者;5例(20%)使用了RFA。中位随访41个月后,局部复发率为33%;无转移生存率为93.3%,总生存率为87.5%。
在患有VHL的患者中,88%有肾脏受累情况的患者需要对其肾脏进行干预。OPN是主要使用的方法,在60%的病例中作为初次和二次手术均取得成功。由于当前技术的限制,仅20%的患者可行RFA。引入基于方案的靶向治疗有望减少治疗VHL所需的干预次数。